VXL — Vaxil Bio Income Statement
0.000.00%
Last trade - 00:00
- CA$2.05m
- CA$1.05m
- 34
- 20
- 40
- 22
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 1.04 | 1.14 | 1.35 | 0.986 | 0.584 |
Operating Profit | -1.04 | -1.14 | -1.35 | -0.986 | -0.584 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -1.05 | -1.15 | -1.36 | -0.986 | -0.584 |
Net Income After Taxes | -1.05 | -1.15 | -1.36 | -0.986 | -0.584 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.05 | -1.15 | -1.36 | -0.986 | -0.584 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.05 | -1.15 | -1.36 | -0.986 | -0.584 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.012 | -0.013 | -0.013 | -0.007 | -0.004 |